Partners

enanta-partners

A Valuable Partner

Our unique approach to R&D goes beyond science and makes us an ideal partner for pharmaceutical companies and others working in the HCV and antibacterial arenas. Being nimble, while maintaining focus allows us to work with a variety of partners to bring our research to where it will do the most good.

Today, we are working collaboratively with our partners; AbbVie (the former research-based pharmaceutical business of Abbott Laboratories), Novartis, and the National Institutes of Allergy and Infectious Disease (NIAID), who share our goals of advancing our compounds as quickly as possible in order to treat a variety of serious infections.

Click here to learn more about our partnership opportunities.

abbvie logo

AbbVie (formerly Abbott Laboratories)

In December 2006, Enanta and Abbott announced a worldwide agreement to collaborate on the discovery, development and commercialization of HCV NS3 and NS3/4A protease inhibitors and HCV protease inhibitor-containing drug combinations. Under the agreement, Abbott (now AbbVie) is responsible for and funds all costs associated with the development, manufacture and commercialization activities of ABT-450 and other compounds under this agreement. We received $57 million upon signing the collaboration agreement and Abbott’s simultaneous purchase of Enanta preferred stock. We are eligible to receive additional pre-commercial milestones, as well as, tiered, double-digit royalties based on annual net sales allocable to ABT-450 or to any of our collaborations additional HCV protease inhibitors. Also, for any additional collaborative HCV protease inhibitor product candidate developed under the agreement, Enanta holds an option to fund 40 percent of U.S. development costs and U.S. commercialization efforts (sales and promotion costs) in exchange for 40 percent of any U.S. profits that ultimately achieve regulatory approval and commercialization.

Read the announcement

NATIONAL INSTITUTES OF ALLERGY AND INFECTIOUS DISEASE (NIAID)

National Institutes of Allergy and Infectious Disease (NIAID)

In September 2011, we were awarded a contract from NIAID to fund preclinical and early clinical development of a new class of bridged bicyclic antibiotics known as Bicyclolides. The Bicyclolides are to be used as medical countermeasures against multiple biodefense bacteria found in anthrax, plague and tularemia. The contract has an initial term of 30 months ending on March 30, 2014. NIAID has the option to extend the contract up to 6 times. If each option period is exercised, the contract would be extended until September 29, 2016. The initial award under the initial term was $14.3 million, with the possibility of up to a total of $42.7 million if each option period is exercised by NIAID.

Additionally, Enanta has focused on bicyclolides for the treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant enterococci (VRE) and resistant streptococci.  All current development activities are focused on intravenous and oral formulations of EDP-788, with additional IND-enabling studies in progress. Our preclinical development of EDP-788 is funded under our contract with NIAID, with potential for further NIAID funding of early clinical development

Novartis

Novartis

In February 2012, we entered into a Collaboration and License Agreement with Novartis granting Novartis exclusive, worldwide rights to develop manufacture and commercialize EDP-239, our lead compound from our NS5A inhibitor program, and other NS5A compounds. Novartis is responsible for all costs associated with the development, manufacture and commercialization of EDP-239, EDP-239-containing combinations and any follow-on NS5A inhibitors, as well as funding our efforts to discover follow-on NS5A inhibitors at least through August 2013. We received an upfront payment of $34 million and are eligible to receive additional payments upon Novartis’ achievement of specified clinical, regulatory, and commercial milestones. We are also eligible to receive tiered, double-digit royalty payments on net sales allocable to our NS5A inhibitors and we retain an option for co-detail rights in the U.S.

Read the announcement